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Study Objectives: Impaired sleep has been linked to increased risk of cardiovascular disease 
(CVD), but the underlying mechanisms are still unsettled. We sought to determine how onset of 
impaired sleep affects the risk of established physiological CVD risk factors (i.e., hypertension, 
diabetes, and dyslipidemia). 
Methods: In a longitudinal cohort study with 3 survey waves (2000, 2004, 2008) from the 
Finnish Public Sector study we used repeated information on sleep duration and disturbances to 
determine onset of impaired sleep. Information on development of CVD risk factors, as 
indicated by initiation of medication for hypertension, diabetes, and dyslipidemia was derived 
from electronic medical records within 8 years of follow-up. Data on 45,647 participants was 
structured as two data-cycles to examine the effect of change in sleep (between two waves) on 
incident CVD events. We applied strict inclusion and exclusion criteria to determine 
temporality between changes in sleep and the outcomes. 
Results: While we did not find consistent effects of onset of short or long sleep, we found onset 
of disturbed sleep to predict subsequent risk of hypertension (hazard ratio = 1.22, 95% CI: 1.04-
1.44) and dyslipidemia (HR = 1.17, 95% CI: 1.07-1.29) in fully adjusted analyses.  
Conclusion: Results suggest that onset of sleep disturbances rather than short or long sleep 
mark an increase in physiological risk factors, which may partly explain the higher risk of CVD 
observed among impaired sleepers. 




STATEMENT OF SIGNIFICANCE 
Impaired sleep is among the most frequent complaints at the general practitioner. While a 
growing body of evidence an association between impaired sleep and cardiovascular health, 
less attention has been directed at detangling the underlying mechanisms, which is imperative 
for early preventive strategies.  
We found onset of disturbed sleep to predict physiological CVD risk factors, which may partly 
explain the higher risk of CVD observed among impaired sleepers. Evaluation of habitual 
sleeping patterns may provide additional information in clinical cardiovascular risk assessment; 
by identifying people at higher risk of CVD.  
Further, future studies could benefit from a larger focus on the importance of timing and 




Cardiovascular disease (CVD) is the primary cause of death worldwide,1 making 
identification of new modifiable risk factors a public health priority. While evidence supports 
an association between impaired sleep and CVD,2 the underlying mechanisms are still unclear. 
It has been hypothesized that impaired sleep affects cardiac health through the development of 
diabetes, hypertension, and dyslipidemia,3 conditions which themselves are associated with 
reduced quality of life and increased costs for the individual and society as a whole.4-6  
Short-term experiments and cross-sectional studies have indicated adverse effects of 
impaired sleep on regulation of multiple body systems with detectable changes in glucose 
sensitivity,7,8 blood pressure,9,10 and blood lipid levels.2 Prospective studies also generally 
support a higher risk of diabetes and hypertension among short sleepers,8,10,11 while findings for 
blood lipids are scarce and conflicting.2 A major limitation of these previous studies is that 
measures of sleep were only obtained once, not allowing direct assessment of the effect of onset 
of impaired sleep on subsequent risk of hypertension, diabetes, and dyslipidemia. Such 
temporal distinction is particularly important as the relationship between impaired sleep and 
these disorders may be bidirectional.  
Our aim is to determine how onset of impaired sleep affects subsequent risk of 
hypertension, diabetes, and dyslipidemia building on repeated information on sleep and 
applying strinct predefined inclusion and exclusion criteria to ensure temporality between sleep 
and the outcomes. 
MATERIALS AND METHODS 
Study Population 
Participants were derived from the Finnish Public Sector Study survey-cohort 
(FPSS), initiated in 1997-98 among public sector employees from 10 towns and 5 hospital 
districts, described in detail elsewhere.12,13 Participants are continuously linked to 
comprehensive national drug reimbursement, health, and retirement registers through unique 
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personal identification codes assigned to all permanent Finnish residents. At approximately 4-
year intervals, all employees working at the target organizations, and previous participants who 
have left the organizations, are invited to the survey-cohort. In 2000-02, the survey included 
items on sleep for the first time, and these have been included in every wave since. Our study 
includes information on participants from waves 2000-02 (response rate 68%), 2004-05 
(response rate 67%), and 2008-09 (response rate 69%). The Ethics committees of Helsinki 
University Hospital and the Finnish Institute of Occupational Health approved the study 
protocol, and participants provided informed consent. 
Study Design 
To determine the effect of onset of impaired sleep, we examined the effect of changes 
in sleeping patterns between two successive waves. Development of hypertension, diabetes, and 
dyslipidemia was assessed between the second wave and end of follow-up December 31, 2011, 
from the registries. The three FPSS waves available enabled the construction of two data-cycles 
for analyses as depicted in Figure 1. Participants with data from all three waves could thus 
contribute observations to both data-cycles if they fulfilled the eligibility criteria presented 
below. Our approach is similar to those previously used to model HIV-progression, hormone 
therapy initiation, and lifestyle changes.14-16  
At the beginning of each data-cycle we mimicked the selection procedure of eligible 
study participants applied in a clinical trial to assure that a change in sleep preceded 
development of the disease: 
- Inclusion criteria: Participation in at least 2 successive waves and normal sleep at the 
first time-point. Normal sleep duration was defined as 7-8 h/night. In analyses of 
disturbed sleep, we defined normal sleep as having sleep complaints no more than once 
a week on average. 
- Exclusion criteria: Having been hospitalised with a diagnosis of sleep apnea (Finnish 
ICD-9 code 3472A; ICD-10 G47.3) or having been hospitalized or treated for coronary 
heart disease or stroke (ICD10 I20.0, I21, I22, I46 and I60-I69) within 7 years of the 
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second time-point, Tx+1. In addition, we excluded those having been reimbursed for 
hypertension, diabetes, or medication for dyslipidemia within 7 years of the second 
time-point, Tx+1, in analysis of these outcomes, respectively. Participants with missing 
information on sleep or any of the covariates were also excluded. 
This left us with a total study population of 37,486 women and 8,161 men, who contributed to 
one or both data-cycles. Non-responders of the FPSS survey-cohort were younger and more 
likely to be male and manual workers than participants.12,13 These characteristics were shared 
by participants of only a single wave, who were not eligible for our study. In addition, single 
wave participants were less likely to have a normal sleep duration and undisturbed sleep than 
eligible participants of 2 successive waves. 
Onset of Impaired Sleep 
Habitual sleep duration was assessed from the surveys as the average hours of sleep in half-
hour intervals (from ≤6 to ≥10). Sleep disturbances were assessed by the frequently used 
validated Jenkins Sleep Problem Scale,17 including the average frequency (from 1 = never to 6 
= every night) of: difficulties falling asleep, difficulties maintaining sleep, early morning 
awakenings, and non-restorative sleep. All symptoms correspond to the insomnia-symptoms 
specified by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Onset of 
disturbed sleep was assessed by creating an index (range 1-6) of the average frequency of the 
included sleep complaints. Due to the inclusion criteria, all participants had normal sleep at the 
first time-point, Tx, and onset of the various aspects of impaired sleep was defined as: 
- Onset of short sleep duration: sleeping <7 h/night at time Tx+1. 
- Onset of long sleep duration: sleeping ≥9 h/night at time Tx+1. 
- Onset of disturbed sleep: reporting an average frequency of sleep complaints more than 
once weekly (index score ≥4) at time Tx+1, reflecting a clinically significant level of 
disturbed sleep.18,19 
Hypertension, Diabetes, and Dyslipidemia 
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Using unique personal identification codes, participants were linked to the nationwide 
Prescription Register, which holds automated dispensing data on all outpatient reimbursed 
purchases of prescribed drugs in every Finnish pharmacy ensuring complete coverage for these 
records (excluding inpatient admissions).20 The Finnish National Sickness Insurance scheme 
provides special reimbursement for many chronic diseases, including hypertension and 
diabetes. Entitlement is based on a detailed medical statement prepared by the treating 
physician confirming that the patient meet explicitly predefined diagnostic criteria.21 
Information on grated reimbursement is stored in the Central Reimbursement Register. 
HYPERTENSION  
We defined cases of hypertension at the time they were listed in the Central 
Reimbursement Register as being granted special reimbursement for treatment of chronic 
hypertension during follow-up. Entitlement was based on: repeated evidence of diastolic blood 
pressure >105 mm Hg, or diastolic pressure >95 mm Hg with cardiovascular comorbidities or 
signs of complications; or systolic pressure >200 mm Hg, after 6-month follow-up without 
pharmacological treatment and subsequent 6 months’ pharmacological treatment.21  
TYPE 2 DIABETES  
Diabetes cases were defined at date of being granted special reimbursement for 
treatment for type-2 diabetes during follow-up. Confirmation of diabetes requires physician 
documented evidence of a fasting plasma glucose of ≥7.0 mmol/L, or a non-fasting plasma 
glucose of ≥11.1 mmol/L and symptoms of diabetes, e.g., polyuria, polydipsia, or glucosuria.21  
DYSLIPIDEMIA  
Treatment initiation of statins (ATC code C10AA) – the primary treatment for 
dyslipidemia – was used to identify cases of dyslipidemia at the date of first dispensed 
prescription during follow-up. In Finland, statins are available by prescription only. 
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Participants were linked to electronic medical records and followed from the second 
time-point until the date of the outcome of interest, death, or end of follow-up on December 31, 
2011. 
Covariates 
Employers’ records and national registers provided information on 
sociodemographic characteristics: sex, age, retirement, and occupational status (based on the 
International Standard Classification of Occupations-88).22 Shift work was obtained by survey 
only for employees at the target organizations. Cohabitation and lifestyle factors were obtained 
by survey. Respiratory disorders (chronic obstructive pulmonary disease [COPD] and asthma) 
were defined as a primary diagnosis at hospitalization or granted special reimbursement for 
treatment within three years prior to the first time-point in each data-cycle. Cancer diagnoses 
were obtained from the Finnish Cancer Registry within 5 years prior to the first time-point in 
each data-cycle. Depression was obtained as a self-reported doctor-diagnosed depression and/ 
or a record of purchases of more than 30 defined daily doses (DDD) of antidepressant 
medication (ATC-code N06A) within 3 years prior to the first time-point in each data-cycle. 
Psychological distress was defined as ≥4 symptoms on the 12-item version of the General 
Health Questionnaire.23 The 6-item Trait Anxiety Inventory was used to quantify subjective 
symptoms of anxiety.24 
Statistical Analyses 
With the FPSS-waves structured as 2 data-cycles, results of these were pooled to 
increase statistical power. We modelled the hazard ratio (HR) and corresponding 95% 
confidence intervals (CI) of the individual outcomes associated with onset of impaired sleep 
duration and disturbances in separate models (as shown in Fig. 2). Clustered proportional 
hazards Cox models with participant ID as the cluster variable were used to account for within-
person correlation across data-cycles. Due to similarity of effects between the genders 
(Appendix 1) and the limited power to address effects among men, analyses were performed for 
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men and women together. Participants were followed from the date of the second time-point, 
Tx+1, until granted reimbursement for treatment of hypertension, diabetes, or filled prescription 
for statins, death, or end of follow-up in each data-cycle with “follow-up time,” i.e., time from 
the second time-point as the underlying time-scale. 
We tried to account for the lack of exchangeability between those with persistent 
normal sleep and those who experienced onset of impaired sleep between two waves by 
adjusting for potential confounders from the first time-point in each data-cycle. First, models 
including age (continuous) and sex were carried out. Second, additional potential confounders 
were added: cohabitation (yes/ no), occupational status (upper-grade non-manual, lower-grade 
non-manual, and manual workers), retirement (working, disability retirees, statutory retirees), 
smoking (never smoker, ex-smoker, smoker of 1-14 cigarettes/ day, 15-24 cigarettes/ day, >24 
cigarettes/ day), alcohol consumption (abstainer, 1-16 units/ week, 17-24 units/week, >24 
units/week), physical activity (>2 metabolic equvivalent task [MET] hours/day, ≤2 MET 
h/day), BMI (<18.5, 18.5-25, 25-30, ≥30), respiratory disease (no/ yes), and cancer (no/ yes). 
Lastly, models were further adjusted for psychological distress (no/ yes), depression (no/ yes), 
and anxiety (as the average response-category 1-4 continuously). Confounders were identified 
according to prior knowledge and the methods of directed acyclic graphs.25 
In sensitivity analyses, we restricted the analyses to a healthy subsample without any 
of the outcomes or COPD, asthma, or cancer within 7 years prior to the second time-point, in 
order to reduce confounding arising from the effects of chronic disorders on both sleeping 
patterns and risk of subsequent disease. Similarly, we excluded participants with depression in a 
separate analysis. Reimbursement for chronic hypertension and diabetes requires repeated 
evidence of dysregulation and up to one year of lifestyle and pharmacological interventions, 
and analyses including a one-year lag-time were carried out to further reduce the risk of reverse 
causation. Since shift work (no/ yes) was not collected for participants who had left the study 
organizations adjustment for this was only performed in a sensitivity analysis. To minimize the 
effect of clinical sleep disorders, we further excluded participants using sleep medication 
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(ATC-code N05C) in a sensitivity analysis. As people may be prescribed sleep medication for 
purposes other than impaired sleep, e.g., for psychiatric disorders, and because they may 
experience impaired sleep despite taking sleep medication, these exclusion criteria were not 
applied in the main analysis. Lastly, to accommodate the potential effect of changing sleep 
duration irrespective of initial sleep duration, we conducted a sensitivity analysis examining the 
effect of shortening or prolonging sleep by ≥2 h/night, also including shifts to the extreme 
response categories of sleep duration (≤6 h/night and ≥10 h/night). 
RESULTS 
The study included 45,647 participants of at least 2 successive waves between 2000 
and 2009. Data-cycle 1 included observations from 32,038 participants. The majority of these 
(n = 24,402) also contributed with observations to Data-cycle 2, which included a total of 
38,011 participant-observations. This combined into a total of 70,049 participant-observations 
eligible for analyses. 
The mean follow-up was 7 years in Data-cycle 1 and 3 years in Data-cycle 2. Among 
those with normal sleep duration at the first time-point, 13% experienced onset of short sleep 
and 3% onset of long sleep at the second time-point. Further, 10% of undisturbed sleepers 
experienced onset of disturbed sleep at the subsequent wave. During follow-up, 3% without 
prior hypertension were reimbursed for the disorder, 2% of non-diabetics were reimbursed for 
treatment of diabetes, and 9% without prior statin treatment filled at least one prescription for 
statins. Table 1 shows the baseline characteristics of the study population. The majority of 
participants were female (83%), reflecting the gender distribution of the source population, 
comprising Finnish public sector and hospital employees (77% women). Participants were 
between 18 and 69, with a smaller proportion of those with onset of short or disturbed sleep 
being younger than 40 years of age compared to persistent normal sleepers. Meanwhile, onset 
of long sleep was associated with a higher likelihood of being either younger than 40 years or 
60 years or older. Compared to persistent normal sleepers, those with onset of impaired sleep 
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were more often manual workers, worked shifts, and had adverse lifestyle factors and more 
existing disorders.  
Onset of Impaired Sleep and Risk of Hypertension 
In age- and sex-adjusted analyses, onset of short sleep was associated with a 
higher risk of hypertension (HR=1.25, 95% CI: 1.06-1.47), as seen in Table 2. Additional 
adjustments for confounders, in particular BMI and lifestyle factors, attenuated this association. 
Compared to participants with persistent undisturbed sleep, those with onset of disturbed sleep 
had approximately 20% higher risk of developing hypertension within the following 8 years 
(HR = 1.22: 1.04-1.44 in the fully adjusted analysis). Onset of long sleep was not associated 
with later risk of hypertension (HR = 0.80: 0.55-1.17). 
Onset of Impaired Sleep and Risk of Diabetes  
Onset of impaired sleep did not markedly affect the risk of diabetes in fully 
adjusted analyses, and a higher risk associated with onset of disturbed sleep in the age- and 
sex-adjusted analyses (HR=1.29, 95% CI: 1.09-1.53) was weakened and no longer apparent 
upon further adjustments (Table 2). Similarly, the suggestive higher risks after onset of short 
or long sleep seen in the age- and sex-adjusted analyses disappeared upon further adjustment 
for confounders. 
Onset of Impaired Sleep and Risk of Dyslipidemia 
Compared to persistent normal sleep, onset of short or long sleep was not 
associated with the risk of dyslipidemia as seen in Table 2. Meanwhile, onset of disturbed sleep 
compared to persistent undisturbed sleep was assocated with a higher risk of dyslipidemia in the 
fully adjusted analysis (HR = 1.17: 1.07-1.29). 
Sensitivity Analyses 
Restricting the analyses to a healthy subsample did not alter the associations with 
of onset of disturbed sleep (Table 3). The results were also robust to: exclusion of participant-
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observations with depression, exclusion of participants filling prescriptions for sleep 
medication, additional adjustment for shift-work and inclusion of a one-year lag-time (Table 4). 
Assessing at the effects of shortening or prolonging sleep by ≥2 h yielded results similar to the 
main analyses, except for a higher risk of diabetes after prolonging sleep (HR = 1.42: 0.99-
2.03), which was not seen in the analysis looking at onset of long sleep (Appendix 2). 
DISCUSSION 
We analysed longitudinal observational data with strict temporal requirements in order 
to determine associations between onset of impaired sleep and subsequent risk of hypertension, 
diabetes, and dyslipidemia. We found onset of disturbed sleep to be associated with a higher 
risk of hypertension and dyslipidemia, while the associations observed with onset of short sleep 
was explained by BMI and underlying ill health. There were no clear associations between 
onset of impaired sleep and diabetes. 
A recent randomized pilot trial showed that a nightly one-hour sleep extension among 
short sleepers over a six-week period resulted in lower blood pressure among 13 hypertensive 
patients.26 We therefore hypothesized that onset of habitual short or long sleep might also affect 
risk of hypertension among healthy people. However, we found no effect of changes in sleep 
duration on hypertension, which is also in contrast with recent reviews supporting a cross-
sectional association between sleep duration and hypertension.9-11 This inconsistency may be 
due to problems with reversed causality in cross-sectional studies and the importance of strict 
temporal requirements as those applied in our study should be emphasized. On the other hand, 
we found a higher risk of hypertension among those with onset of disturbed sleep. In line with 
this, associations between symptoms of disturbed sleep and hypertension are generally 
supported in the literature – especially in combination with short sleep.10,27-29  
Experimental studies generally support a negative effect of short-term sleep 
deprivation on glucose metabolism and insulin sensitivity.7 Evidence of a U-shaped association 
between sleep duration and incidence of diabetes is supportet in previous meta-analyses.8, 30 
This association seems stronger in studies with a longer follow-up, and may be confined to 
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men.8 However, these meta-analyses include studies with information on sleep at one time-
point only, which hampers assessment of the effect of changes in sleep on diabetes risk. 
Looking at onset of impaired sleep, we found no convincing evidence of a relation between 
sleep and diabetes. These findings are in line with a recently published study from the 
Whitehall cohort, where a decrease in sleep duration was not associated with diabetes risk.31 In 
a sensitivity analysis, we found a higher risk of diabetes among those who prolonged their sleep 
by at least 2 hours, suggesting effects of larger shifts in sleep duration rather than movements 
across a predefined cutoff for long sleep. This is also in agreement with findings from the 
Whitehall study, similarly showing a higher risk of diabetes in association with a ≥2-hour/ night 
increase in sleep duration. The results of our study may differ from previous findings due to the 
gender distribution of our study, comprising 84% women, which hampers direct assessment of 
gender differences supported in previous studies.8 Further, the mean follow-up in our study was 
just 4.8 years. If effects of impaired sleep are indeed stronger with longer follow-up, we may 
have had insufficient power to detect weaker associations within a shorter timeframe. Our 
definition of impaired sleep as onset rather than prevalent impaired sleep may also have yielded 
insufficient induction time for effects of impaired sleep on diabetes risk. 
Evidence on the association between impaired sleep and dyslipidemia is scant. 
Experimental studies generally show adverse effects of sleep restriction and fragmentation on 
lipid profiles in healthy volunteers.32,33 Results from population studies have been conflicting 
and mostly comprised restricted samples.2,32,34-37 We found a higher risk of dyslipidemia among 
participants with onset of disturbed sleep, while onset of short and long sleep did not predict 
dyslipidemia in fully adjusted analyses. In contrast to our findings, two cross-sectional studies 
have previously shown adverse lipid levels38 and self-reported hypercholestrolemia39 in women, 
but not men, with short or long sleep. 
Limitations and Strengths 
Systematic measurement of blood pressure, insulin sensitivity, and blood lipids in all 
participants would have been preferable, but is seldom attainable in large longitudinal studies. 
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However, legislation and economic incentives promote a high degree of completeness and 
accuracy of the recordings of dispensed prescription drugs.20 Further, reimbursements for 
chronic hypertension and diabetes follow explicit protocols of clinical assessment, which 
reduce the risk of false-positives. Conversely, while strict clinical requirements ensure a high 
degree of specificity, sensitivity is comparatively low. Examination by a physician is required 
to be diagnosed, and diagnosed patients need to actively apply for reimbursement. Further, the 
partial out of pocket payment for statins may have precluded some patients from following 
assigned treatment. Hence, undiagnosed, untreated, and/ or unreimbursed cases will not be 
identified when relying solely on the register information. Further, detection may be 
socioeconomically patterned. If we assume that lower socioeconomic status is associated with 
onset of impaired sleep (as suggested in Table 1) and also with a lower likelihood of seeking 
medical assistance and subsequent reimbursement as well as being less likely to purchase 
prescribed medication, this misclassification may have resulted in conservative estimates of the 
relations.  
Another source of detection bias may occur if participants with impaired sleep are 
more likely to see a doctor and consequently of having an underlying condition detected. If so, 
the causal relation may be weaker than reflected in our analyses. Whereas reimbursement for 
hypertension and diabetes rely on specific diagnostic criteria, the information on statins does 
not include the indication for prescription, which is not limited to dyslipidemia. Rather, statins 
are prescribed as a general precaution for individuals considered at high risk of CVD.40 So, 
while the use of the universal drug reimbursement system in Finland and availability of statins 
by prescription only ensures comprehensive data on statin purchases,41 perhaps this betters 
reflects a more general cardiac risk marker than dyslipidemia per se.4 However, being among 
the first large-scale studies on the association between impaired sleep and dyslipidemia, our 
study provides new information which adds to current cardiovascular sleep research.  
We assessed sleep using self-report, which is the most common method in large-scale 
research; self-reported information on sleep also forms the basis for diagnosing insomnia in 
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sleep clinics.18 While objective sleep recordings using, e.g., polysomnography would have 
yielded more accurate measures of sleep duration, these are seldom available in large cohort 
studies, such as ours. There is great heterogeneity concerning the operationalization of 
disturbed sleep across studies. We applied insomnia-related symptoms to reflect a clinically 
significant level of impaired sleep.18,19 In the FPSS, a strong correlation between self-reported 
disturbed sleep and prescribed sleep medication (ATC-code N05C) has previously been 
reported.12 Meanwhile, other studies have used more global questions of general sleep quality 
or sleep dissatisfaction, which may contribute to differences in results across studies. Similarly, 
some studies have examined associations with more extreme levels of short and long sleep than 
applied here, and stronger associations may have been expected had we addressed more severe 
levels of impaired sleep.  
Participants with underlying sleep disorders may be of concern, and although we 
excluded participants hospitalized with sleep apnea, this is an underdiagnosed disorder and only 
a fraction of cases are hospitalized.42 To address this issue, we further excluded participants 
taking sleep medication. This did not materially alter the results, and we doubt that underlying 
sleep disorders explain the associations seen in our study. Another matter concerns our 
operationalization of normal sleep. While our operationalisation of disturbed sleep is based on 
established definitions of insomnia,18,19 the choice to define the optimal sleep duration as 7-8 
hours/night can be debated. There is no clinically agreed upon optimal sleep duration, although 
the lowest risk of cardiovascular disease is often observed in this sleep range.43 While the 
majority of study participants report sleep duration within this range, there will be individuals 
for whom shorter or longer sleep duration would reflect an optimal sleep length. As 
determination of the optimal sleep duration at an individual level is not feasible we relied on 7-
8 hours/night as being the range most likely to capture the optimal sleep duration for the 
majority of study participants. To capture the effect of changing sleep duration for the normal 
short and long sleepers, we conducted a sensitivity analysis looking at the effect of shortening 
and prolonging sleep duration at least 2 hours, irrespective of initial sleep duration. These 
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results proved very similar to those of the main analysis, except for the higher risk of diabetes 
followed by prolonging sleep, which was not apparent in the main analyses.  
The major strengths of our study comprise the high statistical power and the use of 
repeat measurements of sleep, enabling determination of the association with onset of impaired 
sleep. Further, use of nationwide registers to determine initiation of treatment for chronic 
hypertension and diabetes as well statins initiation, confer strengths of our study.  
Conclusion 
We found onset of disturbed sleep to be associated with a higher risk of 
hypertension and dyslipidemia within seven years of follow-up. Meanwhile modest or no 
associations with hypertension, diabetes, and dyslipidemia were observed for onset of short or 
long sleep. This suggests that onset of sleep disturbances rather than short or long sleep mark an 




Figure 1. Measurement time-points for the two data-cycles. Tx, Participants with normal sleep and without the 
preexisting outcome in question; Tx+1. Onset of impaired sleep was measured and participants were still without 
the outcome in question. 
 
Figure 2. Flowchart showing the selection of eligible participant-observations for the individual analyses 
*Participants from the town of Tampere are not linked to the prescription register, hence no information on 





ATC: Anatomical Therapeutic Chemical Classification System 
BMI: Body mass index 
CI: Confidence interval 
COPD: Chronic obstructive pulmonary disease 
CVD: Cardiovascular disease 
DDD: Defined daily doses 
FPSS: Finnish Public Sector Study 
H: hours 
HR: Hazard ratio  
ICD: International Classification of Diseases 
IR: Incidence rate  
MET: Metabolic equivalent task 
mm Hg: millimeter of mercury 
n: number 
OSA: Obstructive sleep apnea syndrome 
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Table 1. Baseline characteristics of the 70,049 participant-observations from the Finnish 




Sleep duration Disturbed sleep 
 Onset of  
short sleep  
(<7 h/night) 
 Persistent  
normal sleep 
 (7-8 h/night) 
Onset of long sleep 
(≥9 h/night) No 
Onset of 
disturbed sleep 
 70,049 6,641 43,235 1,616 53,955 6,008 
Women, n (%) 57,947 (83) 5,421 (82) 36,120 (84) 1,414 (88) 44,197 (82) 5,154 (86) 
Age <40, n (%) 18,504 (26) 1,594 (24) 12,455 (29) 503 (31) 15,601 (29) 1,259 (21) 
Age 40-60, n (%) 47,723 (68) 4,764 (72) 28,521 (66) 968 (60) 35,510 (66) 4,480 (75) 
Age ≥ 60, n (%) 3,822 (5) 283 (4) 2,259 (5) 145 (9) 2,844 (5) 269 (4) 
Shift work a, n (%) 21,686 (33) 2,161 (34) 12,620 (31) 592 (39) 16,423 (32) 1,974 (35) 
Manual workers, n (%) 9,292 (13) 1,081 (16) 4,856 (11) 202 (13) 6,745 (13) 923 (15) 
Living alone, n (%) 16,320 (23) 1,585 (24) 9,511 (22) 434 (27) 12,187 (23) 1,462 (24) 
Stressb, n (%) 17,136 (24) 1,794 (27) 9,032 (21) 396 (25) 9,808 (18) 1,818 (30) 
Depressionc, n (%)  9,411 (13) 919 (14) 5,093 (12) 329 (20) 5,378 (10) 1,059 (18) 
Mean trait anxiety (SD) 1.9 (0.6) 2.0 (0.6) 1.9 (0.5) 1.9 (0.6) 1.8 (0.5) 2.0 (0.5) 
Physically inactived, n (%) 16,558 (24) 1,591 (24) 9,464 (22) 421 (26) 12,109 (22) 1,564 (26) 
Smokers, n (%) 10,926 (16) 1,191 (18) 6,002 (14) 221 (14) 8,152 (15) 1,079 (18) 
High risk alcohol intakee, n (%) 5,792 (8) 580 (9) 3,412 (8) 135 (8) 4,124 (8) 567 (9) 
Obesef, n (%) 8,403 (12) 880 (13) 4,659 (11) 221 (14) 6,047 (11) 802 (13) 
Previous hypertension, n (%) 6,350 (9) 649 (10) 3,478 (8) 173 (11) 4,367 (8) 634 (11) 
Previous diabetes, n (%) 1,363 (2) 141 (2) 745 (2) 46 (3) 965 (2) 131 (2) 
Previous dyslipidaemiag, n (%) 5,728 (10) 511 (9) 3,275 (9) 184 (13) 9,988 (9) 537 (11) 
Respiratory disordersh, n (%) 2,624 (4) 259 (4) 1,524 (4) 96 (6) 1,845 (3) 271 (5) 
Cancer, n (%) 1,283 (2) 118 (2) 765 (2) 42 (3) 909 (2) 156 (3) 
 aAmong the 64,275 participants working at the target organizations at baseline. b≥4 symptoms on the 12-item General Health Questionnaire. 
cSelf-reported diagnosis of depression and/or register record of > 30 defined daily doses of anti-depressant medication (ATC codes N06A) in the 3 
years prior to baseline. d≤2 metabolic equivalent task hours/day. e>16 units/week for women and >24 units/week for men. fBody mass index≥30. 









Table 2. Onset of impaired sleep and hazard ratios for hypertension, 






Age- & sex-adjusted 
HR (95% CI) 
Multiple Adjusteda 
HR (95% CI) 
+ Mental health 
adjustedb HR (95% CI) 
Hypertension    
Sleep duration      
Onset of short sleep  
(<7 h/night) 
177 622 1.25 (1.06-1.47) 1.15 (0.98-1.35) 1.13 (0.96-1.33) 
Persistent normal sleep 
(7-8 h/night) 
924 484 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of long sleep  
(≥9 /night) 
28 411 0.87 (0.60-1.27) 0.80 (0.55-1.17) 0.80 (0.55-1.17) 
Disturbed sleep      
No 1,165 489 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of disturbed sleep 180 687 1.35 (1.16-1.59) 1.26 (1.07-1.47) 1.22 (1.04-1.44) 
Diabetes     
Sleep duration      
Onset of short sleep  
(<7 h/night) 
157 504 1.15 (0.97-1.37) 1.01 (0.85-1.20) 0.99 (0.83-1.18) 
Persistent normal sleep 
(7-8 h/night) 
850 414 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of long sleep  
(≥9 h/night) 
40 540 1.34 (0.97-1.85) 1.13 (0.82-1.57) 1.11 (0.80-1.54) 
Disturbed sleep      
No 1,053 411 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of disturbed sleep 161 555 1.29 (1.09-1.53) 1.15 (0.97-1.36) 1.12 (0.95-1.33) 
Dyslipidaemia      
Sleep duration      
Onset of short sleep  
(<7 h/night) 
511 2,173 1.08 (0.98-1.19) 1.03 (0.94-1.14) 1.02 (0.93-1.12) 
Persistent normal sleep 
(7-8 h/night) 
2,958 1,914 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of long sleep  
(≥9 h/night) 
120 2,082 1.10 (0.91-1.32) 1.05 (0.88-1.26) 1.03 (0.85-1.23) 
Disturbed sleep      
No 3,631 1,868 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of disturbed sleep 545 2,559 1.27 (1.16-1.39) 1.21 (1.10-1.32) 1.17 (1.07-1.29) 
AAdjusted for age, sex, cohabitation, occupational class, retirement, smoking, alcohol, BMI, physical activity, respiratory 
disorders (COPD and asthma) and cancer. b+ Additional adjustment for stress, depression, and anxiety. CI, confidence 
interval; HR, hazard ratio; IR, incidence rate; ref., reference; yr, year.
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Table 3. Onset of impaired sleep and hazard ratios for hypertension, diabetes, 






Age- & sex-adjusted 
HR (95% CI) 
Multiple  adjustedb 
HR (95% CI) 
+ Mental health adjustedc 
HR (95% CI) 
Hypertension    
Sleep duration      
Onset of short sleep  
(<7 h/night) 
107 517 1.23 (1.00-1.51) 1.14 (0.93-1.40) 1.12 (0.91-1.38) 
Persistent normal sleep 
(7-8 h/night) 
571 407 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of long sleep  
(≥9 h/night) 
20 396 1.02 (0.65-1.59) 0.95 (0.61-1.49) 0.95 (0.61-1.49) 
Disturbed sleep      
No 732 416 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of disturbed sleep 111 590 1.35 (1.11-1.65) 1.28 (1.04-1.56) 1.24 (1.01-1.53) 
Diabetes     
Sleep duration      
Onset of short sleep  
(<7 h/night) 
60 287 1.12(0.85-1.48) 0.99 (0.75-1.30) 0.97 (0.74-1.28) 
Persistent normal sleep 
(7-8 h/night) 
341 241 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of long sleep  
(≥9 h/night) 
13 255 1.16 (0.67-2.03) 0.98 (0.56-1.73) 0.97 (0.55-1.71) 
Disturbed sleep      
No 447 252 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of disturbed sleep 54 283 1.06 (0.80-1.41) 0.97 (0.73-1.29) 0.96 (0.72-1.28) 
Dyslipidaemia      
Sleep duration      
Onset of short sleep  
(<7 h/night) 
366 1,837 1.04 (0.93-1.16) 1.00 (0.90-1.12) 0.99 (0.88-1.10) 
Persistent normal sleep 
(7-8 h/night) 
2,274 1,675 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of long sleep  
(≥9 h/night) 
88 1,799 1.11 (0.90-1.38) 1.07 (0.86-1.33) 1.04 (0.84-1.29) 
Disturbed sleep      
No 2,770 1,623 1 (ref.) 1 (ref.) 1 (ref.) 
Onset of disturbed sleep 400 2,233 1.26 (1.14-1.41) 1.21 (1.08-1.34) 1.16 (1.04-1.30) 
aWithout prior diabetes, hypertension, dyslipidaemia, respiratory disorders, or cancer, also excluding participants from 
Tampera witout information on statins. bAdjusted for age, sex, cohabitation, occupational class, retirement, smoking, alcohol, 
BMI, and physical activity. c+ Additional adjustment for stress, depression, and anxiety. CI, confidence interval; HR, hazard 
ratio; IR, incidence rate; ref., reference; yr, year.
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Table 4. Sensitivity Analyses – onset of impaired sleep and hazard ratios for hypertension, 
diabetes, and dyslipidemia 
 Sleep duration Disturbed sleep 
Onset of short sleep  
(<7 h/night) 
Persistent normal sleep 
(7-8 h/night) 
Onset of long sleep  
(≥9 h/night) 
No 
Onset of disturbed 
sleep 
Participants without depressiona     
Hypertension                                
No. of cases 155 798 23 1,037 149 
IR/100,000 years 629 470 409 479 684 
Adjustedb HR (95% CI) 1.17 (0.99-1.40) 1 (ref.) 0.84 (0.55-1.27) 1 (ref.) 1.25 (1.05-1.49) 
Diabetes                                                        
No. of cases 134 708 27 922 126 
IR/100,000 years 496 388 444 397 524 
Adjustedb HR (95% CI) 1.05 (0.87-1.27) 1 (ref.) 1.05 (0.71-1.56) 1 (ref.) 1.13 (0.94-1.37) 
Dyslipidemia      
No. of cases 414 2,496 86 3,148 439 
IR/100,000 years 2,025 1,810 1,791 1,781 2,483 
Adjustedb HR (95% CI) 1.01 (0.91-1.12) 1 (ref.) 0.98 (0.79-1.22) 1 (ref.) 1.21 (1.09-1.34) 
Participants without prescription of sleep medicationc     
Hypertension                                
No. of cases 173 891 28 1,139 174 
IR/100,000 years 632 480 427 487 701 
Adjustedd HR (95% CI) 1.16 (0.98-1.36) 1 (ref.) 0.83 (0.57-1.22) 1 (ref.) 1.26 (1.06-1.48) 
Diabetes                                                        
No. of cases 146 810 39 1,022 151 
IR/100,000 years 487 407 549 407 551 
Adjustedd HR (95% CI) 0.97 (0.81-1.16) 1 (ref.) 1.16 (0.83-1.62) 1 (ref.) 1.14 (0.95-1.35) 
Dyslipidaemia      
No. of cases 483 2,799 110 3,498 496 
IR/100,000 years 2,146 1,868 1,990 1,839 2,476 
Adjustedd HR (95% CI) 1.04 (0.94-1.15) 1 (ref.) 1.01 (0.84-1.23) 1 (ref.) 1.16 (1.05-1.28) 
Working population with additional adjustment for shift-worke     
Hypertension          
No. of cases 170 897 28 1,131 172 
IR/100,000 years 627 494 436 497 685 
Adjustedf HR (95% CI)  1.12 (0.95-1.32) 1 (ref.) 0.83 (0.57-1.21) 1 (ref.) 1.20 (1.01-1.41) 
Diabetes             
No. of cases 149 798 38 989 156 
IR/100,000 years 502 409 546 404 561 
Adjustedf HR (95% CI) 1.01 (0.84-1.20) 1 (ref.) 1.17 (0.84-1.64) 1 (ref.) 1.15 (0.97-1.37) 
Dyslipidaemia      
No. of cases 488 2,787 110 3,438 524 
IR/100,000 years 2,192 1,906 2,028 1,864 2,580 
Adjustedf HR (95% CI) 1.04 (0.94-1.14) 1 (ref.) 1.00 (0.82-1.21) 1 (ref.) 1.17 (1.07-1.29) 
Including a 1 yr lag-time     
Hypertension                                
No. of cases 142 705 18 903 139 
IR/100,000 years 632 467 335 478 666 
Adjustedb HR (95% CI) 1.20 (1.00-1.44) 1 (ref.) 0.68 (0.42-1.09) 1 (ref.) 1.23 (1.02-1.48) 
Diabetes                                                        
No. of cases 138 739 35 912 141 
IR/100,000 years 559 454 599 448 609 
Adjustedb HR (95% CI) 1.00 (0.83-1.21) 1 (ref.) 1.14 (0.80-1.61) 1 (ref.) 1.14 (0.95-1.37) 
Dyslipidaemia      
No. of cases 386 2,296 94 2,810 427 
IR/100,000 years 2,095 1,890 2,074 1,837 2,544 
Adjustedb HR (95% CI) 1.00 (0.89-1.11) 1 (ref.) 1.06 (0.86-1.30) 1 (ref.) 1.18 (1.06-1.31) 
aExcluding participant-observations with self-reported doctor-diagnosed depression and/or a national health register record of purchases of more 
than 30 defined daily doses of anti-depressant medication (ATC codes N06A) in the three years prior to baseline. bAdjusted for age, sex, pseudo-
trial no., follow-up, cohabitation, occupational class, retirement, smoking, alcohol, BMI, physical activity, respiratory disorders (COPD and 
asthma), cancer, stress, depression, and anxiety. cExcluding participants with ≥30 defined daily doses of sleep medication within 3 years of 
baseline.  dAdjusted for age, sex, pseudo-trial no., follow-up, cohabitation, occupational class, retirement, smoking, alcohol, BMI, physical activity, 
stress, and anxiety. eExcluding retired participants and participants no longer employed at the project organizations. fAdjusted for age, sex, 
pseudo-trial no., follow-up, cohabitation, occupational class, smoking, alcohol, BMI, physical activity, stress, depression, anxiety, and shift work. 




Appendix 1. Onset of impaired sleep and hazard ratios for hypertension, diabetes, and 
dyslipidemia among 12,102 male and 57,947 female participant-observations 
 Sleep duration Disturbed sleep 
Onset of short sleep  
(<7 h/night) 
Persistent normal sleep 
(7-8 h/night) 
Onset of long sleep  
(≥9 h/night) 
No 
Onset of disturbed 
sleep 
Women     
Hypertension                                
No. of cases 125 717 21 874 142 
IR/100,000 years 533 446 345 443 623 
Adjusteda HR (95% CI) 1.05 (0.87-1.28) 1 (ref.) 0.70 (0.45-1.09) 1 (ref.) 1.17 (0.98-1.41) 
Diabetes                                                        
No. of cases 110 668 29 770 126 
IR/100,000 years 430 388 340 364 503 
Adjusteda HR (95% CI) 0.92 (0.75-1.12) 1 (ref.) 0.95 (0.65-1.39) 1 (ref.) 1.15 (0.95-1.40) 
Dyslipidemia      
No. of cases 403 2,340 103 2,819 458 
IR/100,000 years 2,045 1,757 1,964 1,711 2,428 
Adjusteda HR (95% CI) 1.04 (0.93-1.16) 1 (ref.) 1.04 (0.85-1.27) 1 (ref.) 1.10 (0.87-1.38) 
Men     
Hypertension                                
No. of cases 52 207 7 291 38 
IR/100,000 years 1046 690 958 704 1113 
Adjusteda HR (95% CI) 1.37 (1.00-1.88) 1 (ref.) 1.29 (0.60-2.78) 1 (ref.) 1.41 (0.99-2.03) 
Diabetes                                                        
No. of cases 47 182 11 283 35 
IR/100,000 years 840 553 1361 629 888 
Adjusteda HR (95% CI) 1.24 (0.89-1.72) 1 (ref.) 1.78 (0.87-3.64) 1 (ref.) 1.03 (0.72-1.48) 
Dyslipidaemia      
No. of cases 108 618 17 812 87 
IR/100,000 years 2,837 2,893 3,263 2,740 3,574 
Adjusteda HR (95% CI) 0.94 (0.76-1.17) 1 (ref.) 1.01 (0.64-1.60) 1 (ref.) 1.18 (1.07-1.31) 
AAdjusted for age, cohabitation, occupational class, retirement, smoking, alcohol, BMI, physical activity, respiratory disorders (COPD and asthma), 
cancer, stress, depression, and anxiety. CI, confidence interval; HR, hazard ratio; IR, incidence rate; ref., reference; yr, year.
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Appendix 2. ≥2 hour/night change in sleep and hazard ratios for 







Age- & sex-adjusted 
HR (95% CI) 
Multiple Adjusteda 
HR (95% CI) 
+ Mental health 
adjustedb HR (95% CI) 
Hypertension    
Shortening sleepc  116 659 1.28 (1.06-1.54) 1.16 (0.96-1.40) 1.14 (0.95-1.38) 
Stable sleep duration 1340 503 1 (ref.) 1 (ref.) 1 (ref.) 
Prolonging sleepd 18 525 0.99 (0.62-1.58) 0.88 (0.55-1.40) 0.86 (0.54-1.38) 
Diabetes     
Shortening sleepc 107 547 1.19 (0.98-1.45) 1.00 (0.82-1.22) 0.99 (0.81-1.20) 
Stable sleep duration 1261 438 1 (ref.) 1 (ref.) 1 (ref.) 
Prolonging sleepd 31 838 1.85 (1.30-2.64) 1.46 (1.02-2.10) 1.42 (0.99-2.03) 
Dyslipidaemia      
Shortening sleepc  333 2,263 1.10 (0.98-1.23) 1.03 (0.92-1.15) 1.01 (0.91-1.14) 
Stable sleep duration 4,253 1,969 1 (ref.) 1 (ref.) 1 (ref.) 
Prolonging sleepd 72 2,677 1.24 (0.98-1.58) 1.18 (0.93-1.50) 1.12 (0.88-1.42) 
AAdjusted for age, sex, cohabitation, occupational class, retirement, smoking, alcohol, BMI, physical activity, respiratory 
disorders (COPD and asthma) and cancer. b+ Additional adjustment for stress, depression, and anxiety. c ≥ 2 hours/night 
from the first to the second time-ponit, also including shifts to the extreme response category of short sleep duration 
(≤6 hours/night). d ≥2 hours/night from the first to the second time-ponit, also including shifts to the extreme category 
of long sleep duration (≥10 hours/night). CI, confidence interval; HR, hazard ratio; IR, incidence rate; ref., reference; yr, 
year. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
